Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 51

1.

Correction: Antibody-Targeted Chemotherapy for the Treatment of Melanoma.

Nevala WK, Buhrow SA, Knauer DJ, Reid JM, Atanasova EA, Markovic SN.

Cancer Res. 2019 Sep 1;79(17):4551. doi: 10.1158/0008-5472.CAN-19-1930. No abstract available.

PMID:
31481420
2.

Understanding heterogeneous tumor microenvironment in metastatic melanoma.

Yan Y, Leontovich AA, Gerdes MJ, Desai K, Dong J, Sood A, Santamaria-Pang A, Mansfield AS, Chadwick C, Zhang R, Nevala WK, Flotte TJ, Ginty F, Markovic SN.

PLoS One. 2019 Jun 5;14(6):e0216485. doi: 10.1371/journal.pone.0216485. eCollection 2019.

3.

A pilot clinical trial testing topical resiquimod and a xenopeptide as immune adjuvants for a melanoma vaccine targeting MART-1.

Block MS, Nevala WK, Pang YP, Allred JB, Strand C, Markovic SN.

Melanoma Res. 2019 Aug;29(4):420-427. doi: 10.1097/CMR.0000000000000556.

PMID:
30520800
4.

GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.

Sterner RM, Sakemura R, Cox MJ, Yang N, Khadka RH, Forsman CL, Hansen MJ, Jin F, Ayasoufi K, Hefazi M, Schick KJ, Walters DK, Ahmed O, Chappell D, Sahmoud T, Durrant C, Nevala WK, Patnaik MM, Pease LR, Hedin KE, Kay NE, Johnson AJ, Kenderian SS.

Blood. 2019 Feb 14;133(7):697-709. doi: 10.1182/blood-2018-10-881722. Epub 2018 Nov 21.

PMID:
30463995
5.

Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma.

Mansfield AS, Peikert T, Smadbeck JB, Udell JBM, Garcia-Rivera E, Elsbernd L, Erskine CL, Van Keulen VP, Kosari F, Murphy SJ, Ren H, Serla VV, Schaefer Klein JL, Karagouga G, Harris FR, Sosa C, Johnson SH, Nevala W, Markovic SN, Bungum AO, Edell ES, Dong H, Cheville JC, Aubry MC, Jen J, Vasmatzis G.

J Thorac Oncol. 2019 Feb;14(2):276-287. doi: 10.1016/j.jtho.2018.10.001. Epub 2018 Oct 10.

6.

Non-invasive visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy: a pilot study.

Markovic SN, Galli F, Suman VJ, Nevala WK, Paulsen AM, Hung JC, Gansen DN, Erickson LA, Marchetti P, Wiseman GA, Signore A.

Oncotarget. 2018 Jul 13;9(54):30268-30278. doi: 10.18632/oncotarget.25666. eCollection 2018 Jul 13.

7.

CD206-positive myeloid cells bind galectin-9 and promote a tumor-supportive microenvironment.

Enninga EAL, Chatzopoulos K, Butterfield JT, Sutor SL, Leontovich AA, Nevala WK, Flotte TJ, Markovic SN.

J Pathol. 2018 Aug;245(4):468-477. doi: 10.1002/path.5093. Epub 2018 Jun 28.

PMID:
29732570
8.

Contraction of T cell richness in lung cancer brain metastases.

Mansfield AS, Ren H, Sutor S, Sarangi V, Nair A, Davila J, Elsbernd LR, Udell JB, Dronca RS, Park S, Markovic SN, Sun Z, Halling KC, Nevala WK, Aubry MC, Dong H, Jen J.

Sci Rep. 2018 Feb 1;8(1):2171. doi: 10.1038/s41598-018-20622-8.

9.

Identification of a peptide-peptide binding motif in the coating of nab-paclitaxel nanoparticles with clinical antibodies: bevacizumab, rituximab, and trastuzumab.

Butterfield JT, Kim H, Knauer DJ, Nevala WK, Markovic SN.

Sci Rep. 2017 Nov 3;7(1):14476. doi: 10.1038/s41598-017-15251-6.

10.

Endogenous Heat-Shock Protein Induction with or Without Radiofrequency Ablation or Cryoablation in Patients with Stage IV Melanoma.

Domingo-Musibay E, Heun JM, Nevala WK, Callstrom M, Atwell T, Galanis E, Erickson LA, Markovic SN.

Oncologist. 2017 Sep;22(9):1026-e93. doi: 10.1634/theoncologist.2017-0060. Epub 2017 Jul 5.

11.

Human Melanoma-Derived Extracellular Vesicles Regulate Dendritic Cell Maturation.

Maus RLG, Jakub JW, Nevala WK, Christensen TA, Noble-Orcutt K, Sachs Z, Hieken TJ, Markovic SN.

Front Immunol. 2017 Mar 29;8:358. doi: 10.3389/fimmu.2017.00358. eCollection 2017.

12.

Antibody-targeted paclitaxel loaded nanoparticles for the treatment of CD20+ B-cell lymphoma.

Nevala WK, Butterfield JT, Sutor SL, Knauer DJ, Markovic SN.

Sci Rep. 2017 Apr 5;7:45682. doi: 10.1038/srep45682.

13.

Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients.

Leontovich AA, Dronca RS, Nevala WK, Thompson MA, Kottschade LA, Ivanov LV, Markovic SN; Melanoma Study Group of the Mayo Clinic Cancer Center.

Melanoma Res. 2017 Feb;27(1):32-42. doi: 10.1097/CMR.0000000000000290.

PMID:
27824739
14.

Galectin-9 modulates immunity by promoting Th2/M2 differentiation and impacts survival in patients with metastatic melanoma.

Enninga EA, Nevala WK, Holtan SG, Leontovich AA, Markovic SN.

Melanoma Res. 2016 Oct;26(5):429-41. doi: 10.1097/CMR.0000000000000281.

15.

Antibody-Targeted Chemotherapy for the Treatment of Melanoma.

Nevala WK, Buhrow SA, Knauer DJ, Reid JM, Atanasova EA, Markovic SN.

Cancer Res. 2016 Jul 1;76(13):3954-64. doi: 10.1158/0008-5472.CAN-15-3131. Epub 2016 Apr 28. Erratum in: Cancer Res. 2019 Sep 1;79(17):4551.

16.

T cell Bim levels reflect responses to anti-PD-1 cancer therapy.

Dronca RS, Liu X, Harrington SM, Chen L, Cao S, Kottschade LA, McWilliams RR, Block MS, Nevala WK, Thompson MA, Mansfield AS, Park SS, Markovic SN, Dong H.

JCI Insight. 2016 May 5;1(6). pii: e86014.

17.

Immunologic Autograft Engineering and Survival in Non-Hodgkin Lymphoma.

Porrata LF, Burgstaler EA, Winters JL, Jacob EK, Gastineau DA, Suman VJ, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nevala W, Markovic SN.

Biol Blood Marrow Transplant. 2016 Jun;22(6):1017-1023. doi: 10.1016/j.bbmt.2016.01.024. Epub 2016 Jan 27.

18.

Evidence of Th2 polarization of the sentinel lymph node (SLN) in melanoma.

Grotz TE, Jakub JW, Mansfield AS, Goldenstein R, Enninga EA, Nevala WK, Leontovich AA, Markovic SN.

Oncoimmunology. 2015 Jun 1;4(8):e1026504. eCollection 2015 Aug.

19.

A Versatile Simple Capture Assay for Assessing the Structural Integrity of MHC Multimer Reagents.

Reed BK, Chopp LB, Malo CS, Renner DN, Van Keulen VS, Girtman MA, Nevala WN, Pavelko KD, Gil D, Schrum AG, Johnson AJ, Pease LR.

PLoS One. 2015 Sep 21;10(9):e0137984. doi: 10.1371/journal.pone.0137984. eCollection 2015.

20.

Immune Reactivation by Cell-Free Fetal DNA in Healthy Pregnancies Re-Purposed to Target Tumors: Novel Checkpoint Inhibition in Cancer Therapeutics.

Enninga EA, Nevala WK, Holtan SG, Markovic SN.

Front Immunol. 2015 Aug 26;6:424. doi: 10.3389/fimmu.2015.00424. eCollection 2015. Review.

Supplemental Content

Loading ...
Support Center